Polypharmacology: Challenges and Opportunities in Dr

Journal of Medicinal Chemistry
57, 7874-7887
DOI: 10.1021/jm5006463

Citation Report

#	Article	IF	Citations
1	Multitarget Drugs. , 2008, , 449-472.		5
2	How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Frontiers in Pharmacology, 2014, 5, 231.	1.6	136
3	An in silico target identification using Boolean network attractors: Avoiding pathological phenotypes. Comptes Rendus - Biologies, 2014, 337, 661-678.	0.1	16
4	Computational studies to predict or explain G protein coupled receptor polypharmacology. Trends in Pharmacological Sciences, 2014, 35, 658-663.	4.0	29
5	N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a New Cholinesterase and Monoamine Oxidase Dual Inhibitor. Journal of Medicinal Chemistry, 2014, 57, 10455-10463.	2.9	56
6	Î²-Lactam Estrogen Receptor Antagonists and a Dual-Targeting Estrogen Receptor/Tubulin Ligand. Journal of Medicinal Chemistry, 2014, 57, 9370-9382.	2.9	45
7	First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2014, 5, 1198-1202.	1.7	27
9	Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors â€“ A Structural Perspective of Ligands and Mutants. Scientific Reports, 2015, 5, 13869.	1.6	38
10	Defining the Schistosoma haematobium kinome enables the prediction of essential kinases as anti-schistosome drug targets. Scientific Reports, 2015, 5, 17759.	1.6	37
12	Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors. Angewandte Chemie - International Edition, 2015, 54, 11754-11759.	7.2	51
13	Identification of Orthologous Target Pairs with SharedÂActive Compounds and Comparison of Organismâ€specific Activity Patterns. Chemical Biology and Drug Design, 2015, 86, 1105-1114.	1.5	2
14	Synthetic biology for pharmaceutical drug discovery. Drug Design, Development and Therapy, 2015, 9, 6285.	2.0	66
15	Editorial (Thematic Issue: Multi-Target Drug Discovery in Medicinal Chemistry: Current Status and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	1
16	Repositioning of Thiourea-Containing Drugs as Tyrosinase Inhibitors. International Journal of Molecular Sciences, 2015, 16, 28534-28548.	1.8	28
17	Anticancer Properties of Lamellarins. Marine Drugs, 2015, 13, 1105-1123.	2.2	133
18	Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancement. Drug Design, Development and Therapy, 2015, 9, 4247.	2.0	7
19	Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening. PLoS Computational Biology, 2015, 11, e1004477.	1.5	62
20	Modeling-Enabled Characterization of Novel NLRX1 Ligands. PLoS ONE, 2015, 10, e0145420.	1.1	25

#	Article	IF	Citations
21	Computational polypharmacology comes of age. Frontiers in Pharmacology, 2015, 6, 157.	1.6	61
23	Computer-aided drug discovery. F1000Research, 2015, 4, 630.	0.8	49
24	Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases. Journal of Medicinal Chemistry, 2015, 58, 4964-4975.	2.9	52
25	Design, synthesis and characterization of dual inhibitors against new targets FabG4 and HtdX of Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 2015, 100, 223-234.	2.6	13
26	The design of multitarget ligands for chronic and neuropathic pain. Future Medicinal Chemistry, 2015, 7, 2469-2483.	1.1	37
27	Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids. Oncology Reports, 2015, 34, 1533-1542.	1.2	25
28	Searching Hidden Truth behind Clinical Trials. Respiratory Investigation, 2015, 53, 1.	0.9	0
29	Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors. Journal of Natural Products, 2015, 78, 722-729.	1.5	12
30	Recent Advances in Cancer Therapeutics. Progress in Medicinal Chemistry, 2015, 54, 1-63.	4.1	32
31	Selective, Nontoxic CB₂ Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2015, 58, 2256-2264.	2.9	33
32	Computational Polypharmacology Analysis of the Heat Shock Protein 90 Interactome. Journal of Chemical Information and Modeling, 2015, 55, 676-686.	2.5	31
33	Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 239-243.	1.3	64
34	Selective Optimization of Side Activities (SOSA) in Drug Discovery. , 2015, , 473-486.		2
35	Acute Toxicity-Supported Chronic Toxicity Prediction: A k-Nearest Neighbor Coupled Read-Across Strategy. International Journal of Molecular Sciences, 2015, 16, 11659-11677.	1.8	23
36	Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3665-3670.	1.0	17
37	The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents. Bioorganic and Medicinal Chemistry, 2015, 23, 2408-2423.	1.4	32
38	Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: Dual inhibition of 5-LOX and COX-2 enzymes. European Journal of Medicinal Chemistry, 2015, 97, 104-123.	2.6	49
39	Rational Design of Dual Peptides Targeting Ghrelin and Y₂ Receptors to Regulate Food Intake and Body Weight. Journal of Medicinal Chemistry, 2015, 58, 4180-4193.	2.9	9

#	Article	IF	Citations
40	History and Perspectives of A_{2A}Adenosine Receptor Antagonists as Potential Therapeutic Agents. Medicinal Research Reviews, 2015, 35, 790-848.	5.0	88
41	sc-PDB: a 3D-database of ligandable binding sitesâ€"10 years on. Nucleic Acids Research, 2015, 43, D399-D404.	6.5	182
42	Chemical genetics and regeneration. Future Medicinal Chemistry, 2015, 7, 2263-2283.	1.1	4
43	Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase. European Journal of Medicinal Chemistry, 2015, 106, 157-166.	2.6	32
44	Similarity Mapplet: Interactive Visualization of the Directory of Useful Decoys and ChEMBL in High Dimensional Chemical Spaces. Journal of Chemical Information and Modeling, 2015, 55, 1509-1516.	2.5	23
45	Rationally Designed Small Molecules That Target Both the DNA and RNA Causing Myotonic Dystrophy Type 1. Journal of the American Chemical Society, 2015, 137, 14180-14189.	6.6	106
46	Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2. Journal of Chemical Information and Modeling, 2015, 55, 2079-2084.	2.5	10
47	Using quantitative systems pharmacology for novel drug discovery. Expert Opinion on Drug Discovery, 2015, 10, 1315-1331.	2.5	18
48	Investigations into the binding of jadomycin DS to human topoisomerase IIÎ² by WaterLOGSY NMR spectroscopy. Organic and Biomolecular Chemistry, 2015, 13, 10324-10327.	1.5	12
49	Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms. Chemical Research in Toxicology, 2015, 28, 1875-1887.	1.7	49
50	Multiple binding sites in the nicotinic acetylcholine receptors: An opportunity for polypharmacolgy. Pharmacological Research, 2015, 101, 9-17.	3.1	20
51	Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. Nature Protocols, 2015, 10, 1567-1593.	5.5	481
52	Predicting targets of compounds against neurological diseases using cheminformatic methodology. Journal of Computer-Aided Molecular Design, 2015, 29, 183-198.	1.3	16
53	Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective. Current Pharmaceutical Design, 2016, 22, 3171-3181.	0.9	77
54	Structural insights into the polypharmacological activity of quercetin on serine/threonine kinases. Drug Design, Development and Therapy, 2016, Volume 10, 3109-3123.	2.0	19
55	Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders. Schizophrenia Research and Treatment, 2016, 2016, 1-12.	0.7	47
56	Multiple Targeting Approaches on Histamine H3 Receptor Antagonists. Frontiers in Neuroscience, 2016, 10, 201.	1.4	39
57	Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies. Frontiers in Neuroscience, 2016, 10, 265.	1.4	62

#	Article	IF	Citations
58	Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans. Proteome Science, 2016, 15, 16.	0.7	12
59	Incorporating Natural Products, Pharmaceutical Drugs, Self-Care and Digital/Mobile Health Technologies into Molecular-Behavioral Combination Therapies for Chronic Diseases. Current Clinical Pharmacology, 2016, 11, 128-145.	0.2	26
60	Systems psychopharmacology: A network approach to developing novel therapies. World Journal of Psychiatry, 2016, 6, 66.	1.3	15
61	Natureâ€Inspired Multifunctional Ligands: Focusing on Amyloidâ€Based Molecular Mechanisms of Alzheimer's Disease. ChemMedChem, 2016, 11, 1309-1317.	1.6	31
62	Analyzing Promiscuity at the Level of Active Compounds and Targets. Molecular Informatics, 2016, 35, 583-587.	1.4	8
63	Predicting Molecular Targets for Smallâ€Molecule Drugs with a Ligandâ€Based Interaction Fingerprint Approach. ChemMedChem, 2016, 11, 1352-1361.	1.6	17
64	Polypharmacology in Drug Development: A Minireview of Current Technologies. ChemMedChem, 2016, 11, 1211-1218.	1.6	39
65	Epigenetic polypharmacology: from combination therapy to multitargeted drugs. Clinical Epigenetics, 2016, 8, 105.	1.8	113
66	Enhancing the Enrichment of Pharmacophore-Based Target Prediction for the Polypharmacological Profiles of Drugs. Journal of Chemical Information and Modeling, 2016, 56, 1175-1183.	2.5	163
67	Polypharmacology of dopamine receptor ligands. Progress in Neurobiology, 2016, 142, 68-103.	2.8	57
68	C-Glycosylflavones Alleviate Tau Phosphorylation and Amyloid Neurotoxicity through GSK3Î² Inhibition. ACS Chemical Neuroscience, 2016, 7, 912-923.	1.7	50
69	The evolution of drug discovery: from phenotypes to targets, and back. MedChemComm, 2016, 7, 788-798.	3.5	31
70	Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics. Future Medicinal Chemistry, 2016, 8, 697-711.	1.1	68
71	Derivatives (halogen, nitro and amino) of 8-hydroxyquinoline with highly potent antimicrobial and antioxidant activities. Biochemistry and Biophysics Reports, 2016, 6, 135-141.	0.7	72
72	Chemical Biology Approaches for Characterization of Epigenetic Regulators. Methods in Enzymology, 2016, 574, 79-103.	0.4	5
73	OCEAN: Optimized Cross rEActivity estimatioN. Journal of Chemical Information and Modeling, 2016, 56, 2013-2023.	2.5	10
74	Is imatinib a prototypical example of targeted drug therapy?. Future Medicinal Chemistry, 2016, 8, 1907-1911.	1.1	3
75	BIGCHEM: Challenges and Opportunities for Big Data Analysis in Chemistry. Molecular Informatics, 2016, 35, 615-621.	1.4	85

#	Article	IF	Citations
76	Computational Method for the Systematic Identification of Analog Series and Key Compounds Representing Series and Their Biological Activity Profiles. Journal of Medicinal Chemistry, 2016, 59, 7667-7676.	2.9	50
77	Computational approaches for the study of the role of small molecules in diseases. Perspectives in Science, 2016, 9, 49-52.	0.6	3
78	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. Journal of Medicinal Chemistry, 2016, 59, 8233-8262.	2.9	78
79	Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective. Journal of Medicinal Chemistry, 2016, 59, 9305-9320.	2.9	46
80	The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors. Expert Opinion on Drug Discovery, 2016, 11, 969-981.	2.5	9
81	Exploring Molecular Promiscuity from a Ligand and Target Perspective. ACS Symposium Series, 2016, , 19-34.	0.5	1
82	Charting the chemical space around the (iso)indoline scaffold, a comprehensive approach towards multitarget directed ligands. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4211-4215.	1.0	3
83	Non-Specificity of Drug-Target Interactions â€“ Consequences for Drug Discovery. ACS Symposium Series, 2016, , 91-142.	0.5	2
84	Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke. Scientific Reports, 2016, 6, 25626.	1.6	14
85	Cardiovascular Disease Chemogenomics Knowledgebase-guided Target Identification and Drug Synergy Mechanism Study of an Herbal Formula. Scientific Reports, 2016, 6, 33963.	1.6	32
86	Pharmacological Tool Compounds for the Free Fatty Acid Receptor 4 (FFA4/GPR120). Handbook of Experimental Pharmacology, 2016, 236, 33-56.	0.9	12
87	Studying epigenetic complexes and their inhibitors with the proteomics toolbox. Clinical Epigenetics, 2016, 8, 76.	1.8	15
88	Autophagy as a target for therapeutic uses of multifunctional peptides. IUBMB Life, 2016, 68, 259-267.	1.5	21
89	Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacological Research, 2016, 111, 290-302.	3.1	156
90	Phenotypic Assessment and the Discovery of Topiramate. ACS Medicinal Chemistry Letters, 2016, 7, 662-665.	1.3	16
91	Discovery and development of natural product oridonin-inspired anticancer agents. European Journal of Medicinal Chemistry, 2016, 122, 102-117.	2.6	132
92	DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing. BMC Bioinformatics, 2016, 17, 202.	1.2	19
93	Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorganic and Medicinal Chemistry, 2016, 24, 3671-3679.	1.4	3

#	Article	IF	Citations
94	Metabolomics as a Challenging Approach for Medicinal Chemistry and Personalized Medicine. Journal of Medicinal Chemistry, 2016, 59, 8649-8666.	2.9	46
95	Chemoproteomic Approach to Explore the Target Profile of GPCR ligands: Application to 5â€HT_{1A} and 5â€HT₆ Receptors. Chemistry - A European Journal, 2016, 22, 1313-1321.	1.7	15
96	<scp>ST</scp>09, a Novel Thioester Derivative of Tacrine, Alleviates Cognitive Deficits and Enhances Glucose Metabolism in Vascular Dementia Rats. CNS Neuroscience and Therapeutics, 2016, 22, 220-229.	1.9	14
97	Ensemble-Based Virtual Screening Led to the Discovery of New Classes of Potent Tyrosinase Inhibitors. Journal of Chemical Information and Modeling, 2016, 56, 354-367.	2.5	26
98	The influence of 5-HT 2A activity on a 5-HT 2C specific in vivo assay used for early identification of multiple acting SERT and 5-HT 2C receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 914-920.	1.0	2
99	PatchSurfers: Two methods for local molecular property-based binding ligand prediction. Methods, 2016, 93, 41-50.	1.9	8
100	Matrices for combined delivery of proteins and synthetic molecules. Advanced Drug Delivery Reviews, 2016, 98, 77-85.	6.6	31
101	De Novo Design at the Edge of Chaos. Journal of Medicinal Chemistry, 2016, 59, 4077-4086.	2.9	124
102	Application of Dual Inhibition Concept within Looped Autoregulatory Systems toward Antivirulence Agents against Pseudomonas aeruginosa Infections. ACS Chemical Biology, 2016, 11, 1279-1286.	1.6	61
103	Leveraging Large-scale Behavioral Profiling in Zebrafish to Explore Neuroactive Polypharmacology. ACS Chemical Biology, 2016, 11, 842-849.	1.6	28
104	Photo-cross-linked small-molecule affinity matrix as a tool for target identification of bioactive small molecules. Natural Product Reports, 2016, 33, 709-718.	5.2	29
105	Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?. Annual Review of Neuroscience, 2016, 39, 1-17.	5.0	53
106	Topoisomerase I inhibition and DNA cleavage by zinc, copper, and nickel derivatives of 2-[2-bromoethyliminomethyl]-4-[ethoxymethyl]phenol complexes exhibiting anti-proliferation and anti-metastasis activity. Journal of Inorganic Biochemistry, 2016, 159, 14-21.	1.5	22
107	Phytomedicine polypharmacology: Cancer therapy through modulating the tumor microenvironment and oxylipin dynamics. , 2016, 162, 58-68.		46
108	Non-stoichiometric inhibition in integrated lead finding â€“ a literature review. Expert Opinion on Drug Discovery, 2016, 11, 149-162.	2.5	8
109	One size does not fit all: Challenging some dogmas and taboos in drug discovery. Future Medicinal Chemistry, 2016, 8, 29-38.	1.1	15
110	Systematic assessment of analog relationships between bioactive compounds and promiscuity of analog sets. MedChemComm, 2016, 7, 230-236.	3.5	4
111	Retinoids and rexinoids in cancer prevention: from laboratory to clinic. Seminars in Oncology, 2016, 43, 49-64.	0.8	126

#	Article	IF	Citations
112	Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery. Journal of Medicinal Chemistry, 2016, 59, 2-15.	2.9	31
113	The use of novel selectivity metrics in kinase research. BMC Bioinformatics, 2017, 18, 17.	1.2	35
114	Computational polypharmacology: a new paradigm for drug discovery. Expert Opinion on Drug Discovery, 2017, 12, 279-291.	2.5	86
115	Identification and analysis of promiscuity cliffs formed by bioactive compounds and experimental implications. RSC Advances, 2017, 7, 58-66.	1.7	15
116	Targeting Oxidative Stress in Stroke. Springer Series in Translational Stroke Research, 2017, , 203-250.	0.1	8
117	Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases. Journal of Medicinal Chemistry, 2017, 60, 1400-1416.	2.9	17
118	Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening. Scientific Reports, 2017, 7, 42751.	1.6	33
119	PatchSearch: A Fast Computational Method for Off-Target Detection. Journal of Chemical Information and Modeling, 2017, 57, 769-777.	2.5	8
120	Computational Methods for Processing and Analysis of Biological Pathways. SpringerBriefs in Computer Science, 2017, , .	0.2	5
121	Computational Multitarget Drug Design. Journal of Chemical Information and Modeling, 2017, 57, 403-412.	2.5	149
122	Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery. Drug Discovery Today, 2017, 22, 994-1007.	3.2	28
123	The polypharmacology browser: a web-based multi-fingerprint target prediction tool using ChEMBL bioactivity data. Journal of Cheminformatics, 2017, 9, 11.	2.8	83
124	Design and Synthesis of C3â€Substituted Î²â€Carbolineâ€Based Histone Deacetylase Inhibitors with Potent Antitumor Activities. ChemMedChem, 2017, 12, 646-651.	1.6	29
125	A Multitarget Approach toward the Development of 8â€Substituted Purines for Photoprotection and Prevention of UVâ€Related Damage. ChemMedChem, 2017, 12, 760-769.	1.6	4
126	Polypharmacological in Silico Bioactivity Profiling and Experimental Validation Uncovers Sedative-Hypnotic Effects of Approved and Experimental Drugs in Rat. ACS Chemical Biology, 2017, 12, 1593-1602.	1.6	9
127	In silico polypharmacology of natural products. Briefings in Bioinformatics, 2018, 19, 1153-1171.	3.2	95
128	Outlook for the Future. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 421-447.	0.2	0
129	Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands. ACS Medicinal Chemistry Letters, 2017, 8, 648-653.	1.3	7

#	Article	IF	Citations
130	Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment. Journal of Medicinal Chemistry, 2017, 60, 3626-3635.	2.9	24
131	Exploring the Role of N⁶-Substituents in Potent Dual Acting 5â€²-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice. Journal of Medicinal Chemistry, 2017, 60, 4327-4341.	2.9	15
132	Synthesis and biological evaluation of simplified pironetin analogues with modifications in the side chain and the lactone ring. Organic and Biomolecular Chemistry, 2017, 15, 220-232.	1.5	17
133	Quorum Sensing Inhibitors as Pathoblockers for Pseudomonas aeruginosa Infections: A New Concept in Anti-Infective Drug Discovery. Topics in Medicinal Chemistry, 2017, , 185-210.	0.4	10
134	Structure-Based Discovery of GPCR Ligands from Crystal Structures and Homology Models. Topics in Medicinal Chemistry, 2017, , 65-99.	0.4	3
135	Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimerâ€™s and Other Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2017, 60, 5120-5145.	2.9	40
136	Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy. Bioorganic and Medicinal Chemistry, 2017, 25, 4100-4109.	1.4	64
137	New quinoline-arylamidine hybrids: Synthesis, DNA/RNA binding and antitumor activity. European Journal of Medicinal Chemistry, 2017, 137, 196-210.	2.6	21
138	Stereodivergence in Asymmetric Catalysis. Journal of the American Chemical Society, 2017, 139, 5627-5639.	6.6	353
139	Entering the â€˜big dataâ€™ era in medicinal chemistry: molecular promiscuity analysis revisited. Future Science OA, 2017, 3, FSO179.	0.9	53
140	Networks and Pathways in Systems Pharmacology. SpringerBriefs in Computer Science, 2017, , 11-46.	0.2	4
142	Drugâ€Mediated Regulation of Glycosaminoglycan Biosynthesis. Medicinal Research Reviews, 2017, 37, 1051-1094.	5.0	29
143	Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 323-328.	1.0	4
144	Network-Based Approach to Identify Potential Targets and Drugs that Promote Neuroprotection and Neurorepair in Acute Ischemic Stroke. Scientific Reports, 2017, 7, 40137.	1.6	38
145	Synthesis and Docking of Novel 3â€Indolylpropyl Derivatives as New Polypharmacological Agents Displaying Affinity for 5â€HT_{1A}R/SERT. Archiv Der Pharmazie, 2017, 350, e1600271.	2.1	9
146	Trends in GPCR drug discovery: new agents, targets and indications. Nature Reviews Drug Discovery, 2017, 16, 829-842.	21.5	1,773
147	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. Journal of Medicinal Chemistry, 2017, 60, 8336-8357.	2.9	82
148	Novel p-carborane-containing multitarget anticancer agents inspired by the metabolism of 17Î²-estradiol. Bioorganic and Medicinal Chemistry, 2017, 25, 6371-6378.	1.4	11

#	Article	IF	Citations
149	Design and synthesis of p-carborane-containing sulfamates as multitarget anti-breast cancer agents. Bioorganic and Medicinal Chemistry, 2017, 25, 6417-6426.	1.4	10
150	The potential role of in silico approaches to identify novel bioactive molecules from natural resources. Future Medicinal Chemistry, 2017, 9, 1665-1686.	1.1	27
151	Structural and Functional View of Polypharmacology. Scientific Reports, 2017, 7, 10102.	1.6	33
152	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 7965-7983.	2.9	87
153	Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors. ChemMedChem, 2017, 12, 1449-1457.	1.6	42
154	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. Journal of Medicinal Chemistry, 2017, 60, 7483-7501.	2.9	25
155	Comparison and analysis of the structures and binding modes of antifungal SE and CYP51 inhibitors. Journal of Molecular Graphics and Modelling, 2017, 77, 1-8.	1.3	13
156	Polypharmacology of N⁶-(3-Iodobenzyl)adenosine-5â€²-N-methyluronamide (IB-MECA) and Related A₃ Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) Î³ Partial Agonist and PPARÎ´ Antagonist Activity Suggests Their Antidiabetic Potential. Journal of Medicinal Chemistry, 2017, 60, 7459-7475.	2.9	29
157	Mesua ferrea stem bark extract induces apoptosis and inhibits metastasis in human colorectal carcinoma HCT 116 cells, through modulation of multiple cell signalling pathways. Chinese Journal of Natural Medicines, 2017, 15, 505-514.	0.7	16
158	Polypharmacology of conformationally locked methanocarba nucleosides. Drug Discovery Today, 2017, 22, 1782-1791.	3.2	16
159	Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. Journal of Medicinal Chemistry, 2017, 60, 7447-7458.	2.9	25
161	miRDDCR: a miRNA-based method to comprehensively infer drug-disease causal relationships. Scientific Reports, 2017, 7, 15921.	1.6	14
162	Heat shock protein 90 and serine/threonine kinase B-Raf inhibitors have overlapping chemical space. RSC Advances, 2017, 7, 31069-31074.	1.7	17
163	Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy. Bioorganic and Medicinal Chemistry, 2017, 25, 27-37.	1.4	45
164	Probing an Allosteric Pocket of CDK2 with Small Molecules. ChemMedChem, 2017, 12, 33-41.	1.6	21
165	Molecular mechanisms responsible for programmed cell death-inducing attributes of terpenes from Mesua ferrea stem bark towards human colorectal carcinoma HCT 116 cells. Journal of Applied Biomedicine, 2017, 15, 71-80.	0.6	8
166	Isatin thiazoline hybrids as dual inhibitors of HIV-1 reverse transcriptase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 130-136.	2.5	51
167	Isatin: a privileged scaffold for the design of carbonic anhydrase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 68-73.	2.5	49

#	Article	IF	Citations
168	Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progress in Biophysics and Molecular Biology, 2017, 123, 16-41.	1.4	64
169	CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?. Annual Review of Pharmacology and Toxicology, 2017, 57, 171-187.	4.2	32
170	Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. Journal of Medicinal Chemistry, 2017, 60, 180-201.	2.9	47
171	Virtual Screening for Dual Hsp90/B-Raf Inhibitors. Methods in Pharmacology and Toxicology, 2017, , 355-365.	0.1	0
172	Phytochemicals Approach for Developing Cancer Immunotherapeutics. Frontiers in Pharmacology, 2017, 8, 386.	1.6	42
173	Molecular Connectivity Predefines Polypharmacology: Aliphatic Rings, Chirality, and sp3 Centers Enhance Target Selectivity. Frontiers in Pharmacology, 2017, 8, 552.	1.6	16
174	Receptor Targets in Alzheimerâ€™s Disease Drug Discovery. , 2017, , 83-107.		8
175	Drug Repurposing Review. , 2017, , 11-47.		5
177	Kinase Inhibitors in Multitargeted Cancer Therapy. Current Medicinal Chemistry, 2017, 24, 1671-1686.	1.2	33
178	Computational antioxidant capacity simulation assay of Garcinia kola (Heckel) seed extracts. African Journal of Biotechnology, 2017, 16, 995-1006.	0.3	0
179	Integration of phytochemicals and phytotherapy into cancer precision medicine. Oncotarget, 2017, 8, 50284-50304.	0.8	72
180	Structural Chemogenomics Databases to Navigate Proteinâ€“Ligand Interaction Space. , 2017, , 444-471.		1
181	Repurposing Drugs in Oncology (ReDO)â€”chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience, 2017, 11, 781.	0.6	197
183	Development of a Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-7/-13 Inhibitor. Molecules, 2017, 22, 1548.	1.7	8
184	Allosteric Modulators. , 2017, , 276-296.		5
185	Overview of Drug Polypharmacology and Multitargeted Molecular Design. , 2017, , 259-275.		4
186	Identification of 4â€arylâ€1Hâ€pyrrole[2,3â€b]pyridine derivatives for the development of new Bâ€Raf inhibitors. Chemical Biology and Drug Design, 2018, 92, 1382-1386.	1.5	3
187	Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90). Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1357-1362.	1.0	21

#	Article	IF	Citations
189	Identification of Small-Molecule Inhibitors of Human Golgi Mannosidase via a Drug Repositioning Screen. Chemical and Pharmaceutical Bulletin, 2018, 66, 678-681.	0.6	9
190	Evaluation of Kinase Inhibitor Selectivity Using Cellâ€based Profiling Data. Molecular Informatics, 2018, 37, e1800024.	1.4	2
191	Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinsonâ€™s disease. European Journal of Medicinal Chemistry, 2018, 148, 487-497.	2.6	41
192	Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder. Physical Chemistry Chemical Physics, 2018, 20, 6606-6616.	1.3	125
193	Drug repositioning: current approaches and their implications in the precision medicine era. Expert Review of Precision Medicine and Drug Development, 2018, 3, 49-61.	0.4	48
194	Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 762-768.	1.0	29
195	Novel Pyrimidines as Antitubercular Agents. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	22
196	Computational chemical biology and drug design: Facilitating protein structure, function, and modulation studies. Medicinal Research Reviews, 2018, 38, 914-950.	5.0	38
197	X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design. ACS Omega, 2018, 3, 106-111.	1.6	19
198	Dynamics Determine Signaling in a Multicomponent System Associated with Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2018, 61, 4774-4790.	2.9	2
199	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors. ACS Medicinal Chemistry Letters, 2018, 9, 312-317.	1.3	50
200	Deciphering metabonomics biomarkers-targets interactions for psoriasis vulgaris by network pharmacology. Annals of Medicine, 2018, 50, 323-332.	1.5	10
201	Rationalizing Promiscuity Cliffs. ChemMedChem, 2018, 13, 490-494.	1.6	14
202	Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. European Journal of Medicinal Chemistry, 2018, 143, 449-463.	2.6	46
203	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery. ACS Medicinal Chemistry Letters, 2018, 9, 34-38.	1.3	41
204	Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules. Journal of Chemical Information and Modeling, 2018, 58, 68-89.	2.5	5
205	Quantitative and systems pharmacology 2. In silico polypharmacology of G protein-coupled receptor ligands via network-based approaches. Pharmacological Research, 2018, 129, 400-413.	3.1	28
206	Strategies of Virtual Screening in Medicinal Chemistry. International Journal of Quantitative Structure-Property Relationships, 2018, 3, 134-160.	1.1	12

#	Article	IF	Citations
207	CoDe-DTI: Collaborative Deep Learning-based Drug-Target Interaction Prediction. , 2018, , .		11
208	Privileged Structures and Polypharmacology within and between Protein Families. ACS Medicinal Chemistry Letters, 2018, 9, 1199-1204.	1.3	16
209	Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs. Nature Communications, 2018, 9, 4699.	5.8	13
210	Structure-activity Relationship Studies of New Marine Anticancer Agents and their Synthetic Analogues. Current Medicinal Chemistry, 2018, 24, 4779-4799.	1.2	2
211	Current Approaches to the Isolation and Structural Elucidation of Active Compounds from Natural Products. , 2018, , 209-231.		0
212	Network-Based Methods for Prediction of Drug-Target Interactions. Frontiers in Pharmacology, 2018, 9, 1134.	1.6	131
213	Discovery of the First-in-Class Dual Histone Deacetylaseâ€“Proteasome Inhibitor. Journal of Medicinal Chemistry, 2018, 61, 10299-10309.	2.9	62
214	SAR Matrix Method for Large-Scale Analysis of Compound Structureâ€“Activity Relationships and Exploration of Multitarget Activity Spaces. Methods in Molecular Biology, 2018, 1825, 339-352.	0.4	2
215	Linked Open Data: Ligand-Transporter Interaction Profiling and Beyond. Methods in Pharmacology and Toxicology, 2018, , 405-417.	0.1	0
216	An update on the discovery and development of selective heat shock protein inhibitors as anti-cancer therapy. Expert Opinion on Drug Discovery, 2018, 13, 903-918.	2.5	16
217	Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-Î³ and angiotensin II type 1 receptor. European Journal of Medicinal Chemistry, 2018, 158, 334-352.	2.6	3
218	Computational Multi-Target Drug Design. Methods in Pharmacology and Toxicology, 2018, , 51-90.	0.1	1
219	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. Journal of Medicinal Chemistry, 2018, 61, 5304-5322.	2.9	78
220	Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinsonâ€™s Disease. Journal of Medicinal Chemistry, 2018, 61, 5269-5278.	2.9	40
221	Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6). Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2636-2640.	1.0	15
222	Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections. Journal of Medicinal Chemistry, 2018, 61, 6056-6074.	2.9	84
223	Stereodivergent Synthesis of 3-Aminooxindole Derivatives Containing Vicinal Tetrasubstituted Stereocenters via the Mannich Reaction. Journal of Organic Chemistry, 2018, 83, 8936-8952.	1.7	14
224	Polypharmacology of Berberine Based on Multi-Target Binding Motifs. Frontiers in Pharmacology, 2018, 9, 801.	1.6	23

#	Article	IF	Citations
226	Design, synthesis and pharmacological evaluation of new 3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one derivatives as potential antitumor agents. European Journal of Medicinal Chemistry, 2018, 157, 139-150.	2.6	25
227	Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents. Journal of Medicinal Chemistry, 2018, 61, 7245-7260.	2.9	59
228	Design, synthesis and pharmacological evaluation of novel 2-chloro-3-(1H-benzo[d]imidazol-2-yl)quinoline derivatives as antitumor agents: in vitro and in vivo antitumor activity, cell cycle arrest and apoptotic response. RSC Advances, 2018, 8, 24376-24385.	1.7	12
229	Modeling Small-Molecule Reactivity Identifies Promiscuous Bioactive Compounds. Journal of Chemical Information and Modeling, 2018, 58, 1483-1500.	2.5	28
230	Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis. Journal of Medicinal Chemistry, 2018, 61, 10345-10374.	2.9	67
231	Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets. Journal of Medicinal Chemistry, 2018, 61, 6830-6845.	2.9	31
232	Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4. Journal of Medicinal Chemistry, 2018, 61, 6574-6591.	2.9	55
233	Rational application of drug promiscuity in medicinal chemistry. Future Medicinal Chemistry, 2018, 10, 1835-1851.	1.1	29
234	Reverse screening on indicaxanthin from Opuntia ficus-indica as natural chemoactive and chemopreventive agent. Journal of Theoretical Biology, 2018, 455, 147-160.	0.8	26
235	The role of aryl-topology in balancing between selective and dual 5-HT₇R/5-HT_{1A}actions of 3,5-substituted hydantoins. MedChemComm, 2018, 9, 1033-1044.	3.5	7
236	Chimeric HDAC inhibitors: Comprehensive review on the HDACâ€based strategies developed to combat cancer. Medicinal Research Reviews, 2018, 38, 2058-2109.	5.0	107
237	The Two Faces of Protein Flexibility: A Topological Approach. Current Chemical Biology, 2018, 12, 14-22.	0.2	1
238	Nanotopography-responsive myotube alignment and orientation as a sensitive phenotypic biomarker for Duchenne Muscular Dystrophy. Biomaterials, 2018, 183, 54-66.	5.7	34
239	Effect of missing data on multitask prediction methods. Journal of Cheminformatics, 2018, 10, 26.	2.8	27
240	Selection of protein conformations for structure-based polypharmacology studies. Drug Discovery Today, 2018, 23, 1889-1896.	3.2	22
241	Computational Predictions for Multi-Target Drug Design. Methods in Pharmacology and Toxicology, 2018, , 27-50.	0.1	6
242	Expediting the Design, Discovery and Development of Anticancer Drugs using Computational Approaches. Current Medicinal Chemistry, 2018, 24, 4753-4778.	1.2	18
243	Promising Targets in Anti-cancer Drug Development: Recent Updates. Current Medicinal Chemistry, 2018, 24, 4729-4752.	1.2	56

#	Article	IF	Citations
244	Bacterial Cytological Profiling Reveals the Mechanism of Action of Anticancer Metal Complexes. Molecular Pharmaceutics, 2018, 15, 3404-3416.	2.3	19
245	Advanced Chemometric Modeling Approaches for the Design of Multitarget Drugs Against Neurodegenerative Diseases. Methods in Pharmacology and Toxicology, 2018, , 155-186.	0.1	3
246	Drug Repurposing and Multi-Target Therapies. , 2019, , 780-791.		1
247	Venom of thePhoneutria nigriventerspider alters the cell cycle, viability, and migration of cancer cells. Journal of Cellular Physiology, 2019, 234, 1398-1415.	2.0	10
248	Polypharmacology by Design: A Medicinal Chemistâ€™s Perspective on Multitargeting Compounds. Journal of Medicinal Chemistry, 2019, 62, 420-444.	2.9	314
249	Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D₂ and D₃, while R Enantiomers Engage 5-HT₇. ACS Omega, 2019, 4, 14151-14154.	1.6	11
250	Diflunisal targets the <scp>HMGB</scp> 1/ <scp>CXCL</scp> 12 heterocomplex and blocks immune cell recruitment. EMBO Reports, 2019, 20, e47788.	2.0	34
251	Data structures for compound promiscuity analysis: promiscuity cliffs, pathways and promiscuity hubs formed by inhibitors of the human kinome. Future Science OA, 2019, 5, FSO404.	0.9	3
252	Predicting Potential Drug-Target Interactions with Multi-label Learning and Ensemble Learning. Lecture Notes in Computer Science, 2019, , 726-735.	1.0	0
253	Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. Chemical Reviews, 2019, 119, 10520-10594.	23.0	499
254	Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system. Scientific Reports, 2019, 9, 9841.	1.6	19
255	Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2638-2645.	1.0	26
256	Refinement and Rescoring of Virtual Screening Results. Frontiers in Chemistry, 2019, 7, 498.	1.8	48
257	Activation of pCREB/Nrf-2 signaling mediates re-positioning of liraglutide as hepato-protective for methotrexate -induced liver injury (MILI). Food and Chemical Toxicology, 2019, 132, 110719.	1.8	10
258	Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. Molecules, 2019, 24, 2407.	1.7	30
259	Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs. Nature Structural and Molecular Biology, 2019, 26, 535-544.	3.6	45
260	Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents. MedChemComm, 2019, 10, 1589-1598.	3.5	10
261	Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. Cell Chemical Biology, 2019, 26, 1240-1252.e11.	2.5	15

#	Article	IF	Citations
262	Fingerprinting CANDO: Increased Accuracy with Structure- and Ligand-Based Shotgun Drug Repurposing. ACS Omega, 2019, 4, 17393-17403.	1.6	24
263	R-BIND: An Interactive Database for Exploring and Developing RNA-Targeted Chemical Probes. ACS Chemical Biology, 2019, 14, 2691-2700.	1.6	57
264	Elucidating Compound Mechanism of Action and Predicting Cytotoxicity Using Machine Learning Approaches, Taking Prediction Confidence into Account. Current Protocols in Chemical Biology, 2019, 11, e73.	1.7	1
265	Current computational methods for predicting protein interactions of natural products. Computational and Structural Biotechnology Journal, 2019, 17, 1367-1376.	1.9	36
266	BOVINE WELLFARE HANDLED IN ADAPTED CORRAL WITH UNCONVENTIONAL MATERIALS. Engenharia Agricola, 2019, 39, 272-279.	0.2	0
267	Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. , 2019, 204, 107402.		132
268	Molecular Docking: Shifting Paradigms in Drug Discovery. International Journal of Molecular Sciences, 2019, 20, 4331.	1.8	890
270	Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors. Future Medicinal Chemistry, 2019, 11, 1849-1852.	1.1	8
271	Identifying Protein Features Responsible for Improved Drug Repurposing Accuracies Using the CANDO Platform: Implications for Drug Design. Molecules, 2019, 24, 167.	1.7	24
272	Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction Hotspots. ACS Omega, 2019, 4, 1729-1737.	1.6	18
273	Design and Structural Evolution of Matrix Metalloproteinase Inhibitors. Chemistry - A European Journal, 2019, 25, 7960-7980.	1.7	49
274	Small Multitarget Molecules Incorporating the Enone Moiety. Molecules, 2019, 24, 199.	1.7	15
275	Design, synthesis, and preliminary biological evaluation of 3â€²,4â€²,5â€²-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents. New Journal of Chemistry, 2019, 43, 1874-1884.	1.4	6
276	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. Journal of Medicinal Chemistry, 2019, 62, 6992-7014.	2.9	58
277	Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology. PLoS Computational Biology, 2019, 15, e1006619.	1.5	37
278	The human endogenous metabolome as a pharmacology baseline for drug discovery. Drug Discovery Today, 2019, 24, 1806-1820.	3.2	9
279	Binding site characterization â€“ similarity, promiscuity, and druggability. MedChemComm, 2019, 10, 1145-1159.	3.5	20
280	Towards High-Throughput Chemobehavioural Phenomics in Neuropsychiatric Drug Discovery. Marine Drugs, 2019, 17, 340.	2.2	23

#	Article	IF	Citations
281	Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin. European Journal of Medicinal Chemistry, 2019, 178, 177-194.	2.6	21
282	Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. Molecules, 2019, 24, 1855.	1.7	68
283	Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. Journal of Medicinal Chemistry, 2019, 62, 8881-8914.	2.9	164
284	Triptolide: Medicinal chemistry, chemical biology and clinical progress. European Journal of Medicinal Chemistry, 2019, 176, 378-392.	2.6	98
285	The current status of pharmacotherapy for the treatment of Parkinsonâ€™s disease: transition from single-target to multitarget therapy. Drug Discovery Today, 2019, 24, 1769-1783.	3.2	46
286	Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Current Opinion in Chemical Biology, 2019, 50, 89-100.	2.8	23
287	Prediction of Different Classes of Promiscuous and Nonpromiscuous Compounds Using Machine Learning and Nearest Neighbor Analysis. ACS Omega, 2019, 4, 6883-6890.	1.6	18
288	A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton. Journal of Medicinal Chemistry, 2019, 62, 5176-5190.	2.9	48
289	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry, 2019, 62, 3898-3923.	2.9	60
290	Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy. Bioorganic Chemistry, 2019, 87, 200-208.	2.0	37
291	A Scalable, Multiplexed Assay for Decoding GPCR-Ligand Interactions with RNA Sequencing. Cell Systems, 2019, 8, 254-260.e6.	2.9	22
292	Application of In Silico Drug Repurposing in Infectious Diseases. , 2019, , 427-462.		0
293	Proteochemometric Modeling for Drug Repositioning. , 2019, , 281-302.		7
294	In Silico Modeling of FDA-Approved Drugs for Discovery of Therapies Against Neglected Diseases: A Drug Repurposing Approach. , 2019, , 625-648.		4
295	In Silico Drugâ€“Target Profiling. Methods in Molecular Biology, 2019, 1953, 89-103.	0.4	20
296	Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome. Journal of Computer-Aided Molecular Design, 2019, 33, 559-572.	1.3	8
297	Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer. Steroids, 2019, 150, 108384.	0.8	9
298	Multitarget PPARÎ³ agonists as innovative modulators of the metabolic syndrome. European Journal of Medicinal Chemistry, 2019, 173, 261-273.	2.6	30

#	Article	IF	Citations
299	A Near-IR Fluorescent Dasatinib Derivative That Localizes in Cancer Cells. Bioconjugate Chemistry, 2019, 30, 1175-1181.	1.8	23
300	Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE,) Tj ETQq1 1 0.784314 rgBT /Overloc	1.4	31
301	Automated De Novo Drug Design: Are We Nearly There Yet?. Angewandte Chemie - International Edition, 2019, 58, 10792-10803.	7.2	99
302	Recent Progress in Structure-Based Evaluation of Compound Promiscuity. ACS Omega, 2019, 4, 2758-2765.	1.6	17
303	Automated De Novo Drug Design: Are We Nearly There Yet?. Angewandte Chemie, 2019, 131, 10906-10917.	1.6	12
304	Indole derivatives as multifunctional drugs: Synthesis and evaluation of antioxidant, photoprotective and antiproliferative activity of indole hydrazones. Bioorganic Chemistry, 2019, 85, 568-576.	2.0	83
305	Advances and Challenges in Computational Target Prediction. Journal of Chemical Information and Modeling, 2019, 59, 1728-1742.	2.5	76
306	Identification of FDA-approved drugs targeting the Farnesoid X Receptor. Scientific Reports, 2019, 9, 2193.	1.6	16
307	Harnessing Polypharmacology with Medicinal Chemistry. ACS Medicinal Chemistry Letters, 2019, 10, 273-275.	1.3	90
309	ACID: a free tool for drug repurposing using consensus inverse docking strategy. Journal of Cheminformatics, 2019, 11, 73.	2.8	52
310	Identifying Promiscuous Compounds with Activity against Different Target Classes. Molecules, 2019, 24, 4185.	1.7	17
311	Anticandidal agent for multiple targets: the next paradigm in the discovery of proficient therapeutics/overcoming drug resistance. Future Medicinal Chemistry, 2019, 11, 2955-2974.	1.1	8
313	Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 349-352.	1.0	15
314	Multi-target natural products as alternatives against oxidative stress in Chronic Obstructive Pulmonary Disease (COPD). European Journal of Medicinal Chemistry, 2019, 163, 911-931.	2.6	36
315	Translating GWAS findings into therapies for depression and anxiety disorders: gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning. Psychological Medicine, 2019, 49, 2692-2708.	2.7	18
316	FS-7 inhibits MGC-803 cells growth in vitro and in vivo via down-regulating glycolysis. Biomedicine and Pharmacotherapy, 2019, 109, 1659-1669.	2.5	7
317	Implications of de novo mutations in guiding drug discovery: A study of four neuropsychiatric disorders. Journal of Psychiatric Research, 2019, 110, 83-92.	1.5	3
318	Modeling of the Binding of Octopamine and Dopamine in Insect Monoamine Transporters Reveals Structural and Electrostatic Differences. ACS Chemical Neuroscience, 2019, 10, 2310-2317.	1.7	4

#	Article	IF	Citations
319	Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. Gastroenterology, 2019, 156, 311-324.	0.6	85
320	Repurposing of Approved Cardiovascular Drugs against Ischemic Cerebrovascular Disease by Diseaseâ€“Disease Associated Network-Assisted Prediction. Chemical and Pharmaceutical Bulletin, 2019, 67, 32-40.	0.6	4
321	Discovering the pharmacodynamics of conolidine and cannabidiol using a cultured neuronal network based workflow. Scientific Reports, 2019, 9, 121.	1.6	14
322	The Antioxidant, Anti-Inflammatory, and Sedative Effects of Melatonin: Results of Clinical Trials. Neuroscience and Behavioral Physiology, 2019, 49, 54-59.	0.2	1
323	Hit Dexter 2.0: Machine-Learning Models for the Prediction of Frequent Hitters. Journal of Chemical Information and Modeling, 2019, 59, 1030-1043.	2.5	70
324	The power of combining phenotypic and target-focused drug discovery. Drug Discovery Today, 2019, 24, 526-532.	3.2	34
325	First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent. European Journal of Medicinal Chemistry, 2019, 162, 161-175.	2.6	28
326	Web-Based Tools for Polypharmacology Prediction. Methods in Molecular Biology, 2019, 1888, 255-272.	0.4	23
327	Establishment of in vitro and in vivo anti-colon cancer efficacy of essential oils containing oleo-gum resin extract of Mesua ferrea. Biomedicine and Pharmacotherapy, 2019, 109, 1620-1629.	2.5	17
329	Targeting glutathione S-transferase P and its interactome with selenium compounds in cancer therapy. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 130-143.	1.1	35
330	Bitter and sweet tasting molecules: It's complicated. Neuroscience Letters, 2019, 700, 56-63.	1.0	48
331	Epigenetic polypharmacology: A new frontier for epiâ€drug discovery. Medicinal Research Reviews, 2020, 40, 190-244.	5.0	74
332	Validation strategies for target prediction methods. Briefings in Bioinformatics, 2020, 21, 791-802.	3.2	42
333	Pharmacological approaches to tackle NCLs. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165553.	1.8	6
334	Discovery of novel halogenated 8â€hydroxyquinolineâ€based antiâ€MRSA agents: In vitro and QSAR studies. Drug Development Research, 2020, 81, 127-135.	1.4	11
335	Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets. Journal of Medicinal Chemistry, 2020, 63, 884-904.	2.9	126
336	AntiHIV-Pred: web-resource for in silico prediction of anti-HIV/AIDS activity. Bioinformatics, 2020, 36, 978-979.	1.8	9
337	Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity. Chemical Research in Toxicology, 2020, 33, 154-161.	1.7	9

#	Article	IF	Citations
338	Substituted 4-phenylthiazoles: Development of potent and selective A1, A3 and dual A1/A3 adenosine receptor antagonists. European Journal of Medicinal Chemistry, 2020, 186, 111879.	2.6	9
339	Profiling of LINS01 compounds at human dopamine D2 and D3 receptors. Journal of Chemical Sciences, 2020, 132, 1.	0.7	5
340	Quinolizidine alkaloids derivatives from Sophora alopecuroides Linn: Bioactivities, structure-activity relationships and preliminary molecular mechanisms. European Journal of Medicinal Chemistry, 2020, 188, 111972.	2.6	63
341	Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy. Journal of Medicinal Chemistry, 2020, 63, 122-139.	2.9	41
342	The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker. Chemistry and Biodiversity, 2020, 17, e1900427.	1.0	17
343	Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank. Journal of Chemical Information and Modeling, 2020, 60, 372-390.	2.5	19
344	Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome. Journal of Computer-Aided Molecular Design, 2020, 34, 1-10.	1.3	8
345	Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology, 2020, 45, 622-631.	2.8	63
346	Targeting Enzymes for Pharmaceutical Development. Methods in Molecular Biology, 2020, , .	0.4	2
347	Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity. Acta Pharmaceutica Sinica B, 2020, 10, 1294-1308.	5.7	38
348	Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor Î³. Bioorganic and Medicinal Chemistry, 2020, 28, 115226.	1.4	5
349	Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers. Frontiers in Pharmacology, 2019, 10, 1533.	1.6	12
350	Bifunctional HDAC Therapeutics: One Drug to Rule Them All?. Molecules, 2020, 25, 4394.	1.7	29
351	Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone. Molecules, 2020, 25, 4494.	1.7	8
352	Pain Chemogenomics Knowledgebase (Pain-CKB) for Systems Pharmacology Target Mapping and Physiologically Based Pharmacokinetic Modeling Investigation of Opioid Drugâ€“Drug Interactions. ACS Chemical Neuroscience, 2020, 11, 3245-3258.	1.7	2
353	Sprouts and Microgreens: Trends, Opportunities, and Horizons for Novel Research. Agronomy, 2020, 10, 1424.	1.3	84
354	Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127610.	1.0	9
355	Significance of drug reprofiling and metabolic engineering in drug synthesis. , 2020, , 287-301.		0

#	Article	IF	Citations
356	Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus. European Journal of Medicinal Chemistry, 2020, 207, 112742.	2.6	36
357	HDACâ€"Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells. Journal of Medicinal Chemistry, 2020, 63, 12083-12099.	2.9	13
358	Exploration of the mechanism of traditional Chinese medicine by AI approach using unsupervised machine learning for cellular functional similarity of compounds in heterogeneous networks, XiaoErFuPi granules as an example. Pharmacological Research, 2020, 160, 105077.	3.1	21
359	Network analysis, sequence and structure dynamics of key proteins of coronavirus and human host, and molecular docking of selected phytochemicals of nine medicinal plants. Journal of Biomolecular Structure and Dynamics, 2021, 39, 6195-6217.	2.0	28
360	NetInfer: A Web Server for Prediction of Targets and Therapeutic and Adverse Effects via Network-Based Inference Methods. Journal of Chemical Information and Modeling, 2020, 60, 3687-3691.	2.5	23
361	Design, Synthesis and Evaluation of O â€Pentyne Substituted Diphenylpyrimidines as Monoamine Oxidase and Acetylcholinesterase Inhibitors. ChemistrySelect, 2020, 5, 8021-8032.	0.7	9
362	Moving targets in drug discovery. Scientific Reports, 2020, 10, 20213.	1.6	23
363	Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model. Viruses, 2020, 12, 1325.	1.5	24
364	Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dualâ€Targeting HDAC Inhibitors and HDAC Degraders (PROTACs). Angewandte Chemie - International Edition, 2020, 59, 22494-22499.	7.2	42
365	Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1H)-ones as Polypharmacological Inhibitors of BET and Kinases. Journal of Medicinal Chemistry, 2020, 63, 9787-9802.	2.9	12
366	Properly Substituted Cyclic Bis-(2-bromobenzylidene) Compounds Behaved as Dual p300/CARM1 Inhibitors and Induced Apoptosis in Cancer Cells. Molecules, 2020, 25, 3122.	1.7	4
367	Probing antiviral drugs against SARS-CoV-2 through virus-drug association prediction based on the KATZ method. Genomics, 2020, 112, 4427-4434.	1.3	32
368	Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration. Journal of Medicinal Chemistry, 2020, 63, 14448-14469.	2.9	26
369	Hydroxamic Acids Immobilized on Resins (HAIRs): Synthese von Dualâ€Targetâ€HDACâ€Inhibitoren und HDACâ€PROTACs. Angewandte Chemie, 2020, 132, 22681-22687.	1.6	2
370	Analysis of Biological Screening Compounds with Single- or Multi-Target Activity via Diagnostic Machine Learning. Biomolecules, 2020, 10, 1605.	1.8	13
371	Discovery of 5,5â€²-Methylenedi-2,3-Cresotic Acid as a Potent Inhibitor of the Chemotactic Activity of the HMGB1·CXCL12 Heterocomplex Using Virtual Screening and NMR Validation. Frontiers in Chemistry, 2020, 8, 598710.	1.8	3
372	Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer. Computational and Structural Biotechnology Journal, 2020, 18, 3819-3832.	1.9	6
373	Systematic Data Analysis and Diagnostic Machine Learning Reveal Differences between Compounds with Single- and Multitarget Activity. Molecular Pharmaceutics, 2020, 17, 4652-4666.	2.3	14

#	Article	IF	Citations
374	Identification of proteasome inhibitors using analysis of gene expression profiles. European Journal of Pharmacology, 2020, 889, 173709.	1.7	14
375	Multi-Targeting Bioactive Compounds Extracted from Essential Oils as Kinase Inhibitors. Molecules, 2020, 25, 2174.	1.7	10
376	Synthesis and Biological Evaluation of 2-Substituted Benzyl-/Phenylethylamino-4-amino-5-aroylthiazoles as Apoptosis-Inducing Anticancer Agents. Molecules, 2020, 25, 2177.	1.7	6
377	GalaxySagittarius: Structure- and Similarity-Based Prediction of Protein Targets for Druglike Compounds. Journal of Chemical Information and Modeling, 2020, 60, 3246-3254.	2.5	27
378	FastTargetPred: a program enabling the fast prediction of putative protein targets for input chemical databases. Bioinformatics, 2020, 36, 4225-4226.	1.8	5
379	Sparse feature selection in multi-target modeling of carbonic anhydrase isoforms by exploiting shared information among multiple targets. Chemometrics and Intelligent Laboratory Systems, 2020, 200, 104000.	1.8	4
380	Quantitative prediction of selectivity between the A1 and A2A adenosine receptors. Journal of Cheminformatics, 2020, 12, 33.	2.8	10
381	An up-to-date overview of computational polypharmacology in modern drug discovery. Expert Opinion on Drug Discovery, 2020, 15, 1025-1044.	2.5	44
382	Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor. PLoS ONE, 2020, 15, e0233089.	1.1	19
383	Hybrid molecules based on 1,3,5â€triazine as potential therapeutics: A focused review. Drug Development Research, 2020, 81, 837-858.	1.4	21
384	From combinations to multitargetâ€directed ligands: A continuum in Alzheimer's disease polypharmacology. Medicinal Research Reviews, 2021, 41, 2606-2633.	5.0	88
385	Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis. Molecules, 2020, 25, 1239.	1.7	23
386	Potent arylamide derivatives as dual-target antifungal agents: Design, synthesis, biological evaluation, and molecular docking studies. Bioorganic Chemistry, 2020, 99, 103749.	2.0	22
387	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 4256-4292.	2.9	59
388	Discovery of Multitarget-Directed Ligands Against Influenza A Virus From Compound Yizhihao Through a Predictive System for Compound-Protein Interactions. Frontiers in Cellular and Infection Microbiology, 2020, 10, 16.	1.8	18
389	Biological Activity Profiles of Multitarget Ligands from X-ray Structures. Molecules, 2020, 25, 794.	1.7	2
390	Structure-Based Discovery of Dual-Target Hits for Acetylcholinesterase and the Î±7 Nicotinic Acetylcholine Receptors: In Silico Studies and In Vitro Confirmation. Molecules, 2020, 25, 2872.	1.7	9
391	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. European Journal of Pharmacology, 2020, 883, 173348.	1.7	55

#	Article	IF	Citations
392	Rationally Designed Polypharmacology: Î±â€Helix Mimetics as Dual Inhibitors of the Oncoproteins Mclâ€1â€‰and HDM2. ChemMedChem, 2020, 15, 1691-1698.	1.6	6
393	Drug repositioning based on the target microRNAs using bilateral-inductive matrix completion. Molecular Genetics and Genomics, 2020, 295, 1305-1314.	1.0	5
394	Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data. Molecular Omics, 2020, 16, 474-491.	1.4	33
395	Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-Î² aggregation against Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2020, 202, 112475.	2.6	16
396	Discovery of Novel Inhibitors Targeting Multi-UDP-hexose Pyrophosphorylases as Anticancer Agents. Molecules, 2020, 25, 645.	1.7	9
397	Metabolism of bioconjugate therapeutics: why, when, and how?. Drug Metabolism Reviews, 2020, 52, 66-124.	1.5	14
398	Natural products-based polypharmacological modulation of the peripheral immune system for the treatment of neuropsychiatric disorders. , 2020, 208, 107480.		18
399	The impact of chemoinformatics on drug discovery in the pharmaceutical industry. Expert Opinion on Drug Discovery, 2020, 15, 293-306.	2.5	67
401	Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent inÂvitro and inÂvivo anticancer activity. European Journal of Medicinal Chemistry, 2020, 189, 112073.	2.6	25
402	Discovery of Novel Fungal Lanosterol 14Î±-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis. Journal of Medicinal Chemistry, 2020, 63, 5341-5359.	2.9	45
403	Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors. ChemMedChem, 2020, 15, 1163-1174.	1.6	21
404	Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma. Journal of Medicinal Chemistry, 2020, 63, 4701-4715.	2.9	34
405	Prospects of <scp>multitarget</scp> drug designing strategies by linking molecular docking and molecular dynamics to explore the <scp>proteinâ€“ligand</scp> recognition process. Drug Development Research, 2020, 81, 685-699.	1.4	31
406	Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer. European Journal of Medicinal Chemistry, 2020, 198, 112322.	2.6	15
407	Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities. Bioorganic and Medicinal Chemistry, 2020, 28, 115434.	1.4	21
408	Can machine learning consistently improve the scoring power of classical scoring functions? Insights into the role of machine learning in scoring functions. Briefings in Bioinformatics, 2021, 22, 497-514.	3.2	49
409	Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Seminars in Cancer Biology, 2021, 68, 209-229.	4.3	39
410	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. European Journal of Medicinal Chemistry, 2021, 209, 112904.	2.6	45

#	Article	IF	Citations
411	Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs. European Journal of Pharmaceutical Sciences, 2021, 156, 105594.	1.9	31
412	Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer. European Journal of Medicinal Chemistry, 2021, 211, 113022.	2.6	13
413	Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment. European Journal of Medicinal Chemistry, 2021, 213, 113058.	2.6	18
414	Computer-Aided Drug Design for Cancer Therapy. , 2021, , 386-401.		3
415	Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2021, 30, 115940.	1.4	14
416	Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer. European Journal of Medicinal Chemistry, 2021, 213, 113054.	2.6	20
417	Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. RSC Medicinal Chemistry, 2021, 12, 178-196.	1.7	6
418	Cyclic Peptides as Drugs for Intracellular Targets: The Next Frontier in Peptide Therapeutic Development. Chemistry - A European Journal, 2021, 27, 1487-1513.	1.7	91
419	Prediction of Promiscuity Cliffs Using Machine Learning. Molecular Informatics, 2021, 40, 2000196.	1.4	6
420	Multi-targeted drug design strategies for the treatment of schizophrenia. Expert Opinion on Drug Discovery, 2021, 16, 101-114.	2.5	10
421	Multi-Target Drugs as Master Keys to Complex Diseases: Inverse Docking Strategies and Opportunities. , 2021, , 295-311.		0
422	Protein Structure, Dynamics and Assembly: Implications for Drug Discovery. , 2021, , 91-122.		1
423	Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System. International Journal of Molecular Sciences, 2021, 22, 1001.	1.8	23
424	Adenosine receptors as promising targets for the management of ocular diseases. Medicinal Chemistry Research, 2021, 30, 353-370.	1.1	15
425	An Ensemble Approach Based on Multi-Source Information to Predict Drug-MiRNA Associations via Convolutional Neural Networks. IEEE Access, 2021, 9, 38331-38341.	2.6	11
426	Synthesis and Antileishmanial Evaluation of Arylimidamideâ€“Azole Hybrids Containing a Phenoxyalkyl Linker. ACS Infectious Diseases, 2021, 7, 1901-1922.	1.8	3
427	Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment. Aging, 2021, 13, 6982-6998.	1.4	13
428	Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives. Cancers, 2021, 13, 634.	1.7	96

#	Article	IF	Citations
429	Recent advances in proteomeâ€wide labelâ€free target deconvolution for bioactive small molecules. Medicinal Research Reviews, 2021, 41, 2893-2926.	5.0	13
430	An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. Expert Opinion on Drug Discovery, 2021, 16, 745-761.	2.5	25
431	Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease. Frontiers in Pharmacology, 2021, 12, 636989.	1.6	28
432	Gains from no real PAINS: Where â€˜Fair Trial Strategyâ€™ stands in the development of multi-target ligands. Acta Pharmaceutica Sinica B, 2021, 11, 3417-3432.	5.7	10
433	Multitargeting application of proline-derived peptidomimetics addressing cancer-related human matrix metalloproteinase 9 and carbonic anhydrase II. European Journal of Medicinal Chemistry, 2021, 214, 113260.	2.6	6
434	A landscape for drug-target interactions based on network analysis. PLoS ONE, 2021, 16, e0247018.	1.1	9
435	Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. ACS Pharmacology and Translational Science, 2021, 4, 966-979.	2.5	7
436	Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020). Expert Opinion on Therapeutic Patents, 2021, 31, 609-623.	2.4	15
437	Epigenetic Target Profiler: A Web Server to Predict Epigenetic Targets of Small Molecules. Journal of Chemical Information and Modeling, 2021, 61, 1550-1554.	2.5	16
438	In silico health effect prioritization of environmental chemicals through transcriptomics data exploration from a chemo-centric view. Science of the Total Environment, 2021, 762, 143082.	3.9	4
439	Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. European Journal of Medicinal Chemistry, 2021, 216, 113300.	2.6	28
440	Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A. Cancers, 2021, 13, 1734.	1.7	6
442	Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. Scientific Reports, 2021, 11, 8232.	1.6	53
443	Machine learning reveals that structural features distinguishing promiscuous and non-promiscuous compounds depend on target combinations. Scientific Reports, 2021, 11, 7863.	1.6	14
444	Complex interactions of lovastatin with 10 chemotherapeutic drugs: a rigorous evaluation of synergism and antagonism. BMC Cancer, 2021, 21, 356.	1.1	5
445	Cluster Analysis of Medicinal Plants and Targets Based on Multipartite Network. Biomolecules, 2021, 11, 546.	1.8	7
446	Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular Diversity, 2021, 25, 1315-1360.	2.1	423
447	Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPÎ± and TIGIT/PVR Pathways for Cancer Immuno-Therapy. Biomolecules, 2021, 11, 706.	1.8	21

#	Article	IF	Citations
448	Design, synthesis, and biological evaluation of nitroisoxazole-containing spiro[pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit breast adenocarcinoma cell proliferation. European Journal of Medicinal Chemistry, 2021, 217, 113359.	2.6	34
449	How Physiological Targets Can Be Distinguished from Drug-binding Proteins. Molecular Pharmacology, 2021, 100, MOLPHARM-EMC-2020-000186.	1.0	3
450	Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. Journal of Medicinal Chemistry, 2021, 64, 7839-7852.	2.9	85
451	Diterpenoids from Zhumeria majdae roots as potential heat shock protein 90 (HSP90) modulators. Phytochemistry, 2021, 185, 112685.	1.4	5
452	LigAdvisor: a versatile and user-friendly web-platform for drug design. Nucleic Acids Research, 2021, 49, W326-W335.	6.5	12
453	Thiazolidinedione â€œMagic Bulletsâ€•Simultaneously Targeting PPARÎ³ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects. Journal of Medicinal Chemistry, 2021, 64, 6949-6971.	2.9	20
454	A Study to Decipher the Potential Effects of Butylphthalide against Central Nervous System Diseases Based on Network Pharmacology and Molecular Docking Integration Strategy. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-13.	0.5	2
455	Understanding the Polypharmacological Profiles of Triple Reuptake Inhibitors by Molecular Simulation. ACS Chemical Neuroscience, 2021, 12, 2013-2026.	1.7	18
456	Fine-tuning of a generative neural network for designing multi-target compounds. Journal of Computer-Aided Molecular Design, 2022, 36, 363-371.	1.3	8
457	Adenosine A_{2A}R/A₁R Antagonists Enabling Additional H₃R Antagonism for the Treatment of Parkinsonâ€™s Disease. Journal of Medicinal Chemistry, 2021, 64, 8246-8262.	2.9	6
458	Structured data sets of compounds with multi-target and corresponding single-target activity from biological assays. Future Science OA, 2021, 7, FSO685.	0.9	2
459	Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors. International Journal of Molecular Sciences, 2021, 22, 6070.	1.8	5
460	Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. Journal of Medicinal Chemistry, 2021, 64, 8447-8473.	2.9	28
461	Application of Machine Learning Techniques in Drug-target Interactions Prediction. Current Pharmaceutical Design, 2021, 27, 2076-2087.	0.9	4
462	A Novel Benzopyrane Derivative Targeting Cancer Cell Metabolic and Survival Pathways. Cancers, 2021, 13, 2840.	1.7	3
463	Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach. Cancers, 2021, 13, 2936.	1.7	7
464	Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chemical Biology, 2021, 28, 1433-1445.e3.	2.5	13
465	Ir-Catalyzed Regio- and Enantioselective Hydroalkynylation of Trisubstituted Alkene to Access All-Carbon Quaternary Stereocenters. Journal of the American Chemical Society, 2021, 143, 9639-9647.	6.6	38

#	Article	IF	Citations
466	Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy. Journal of Medicinal Chemistry, 2021, 64, 7963-7990.	2.9	69
467	Structureâ€Guided Design of Gâ€Proteinâ€Coupled Receptor Polypharmacology. Angewandte Chemie, 2021, 133, 18170-18178.	1.6	0
468	A multi-herb-combined remedy to overcome hyper-inflammatory response by reprogramming transcription factor profile and shaping monocyte subsets. Pharmacological Research, 2021, 169, 105617.	3.1	8
469	Ugi Reaction Synthesis of Oxindoleâ€“Lactam Hybrids as Selective Butyrylcholinesterase Inhibitors. ACS Medicinal Chemistry Letters, 2021, 12, 1718-1725.	1.3	13
470	Structureâ€Guided Design of Gâ€Proteinâ€Coupled Receptor Polypharmacology. Angewandte Chemie - International Edition, 2021, 60, 18022-18030.	7.2	12
471	LP1 and LP2: Dual-Target MOPr/DOPr Ligands as Drug Candidates for Persistent Pain Relief. Molecules, 2021, 26, 4168.	1.7	7
472	Compound dataset and custom code for deep generative multi-target compound design. Future Science OA, 2021, 7, FSO715.	0.9	4
473	Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist. Journal of Medicinal Chemistry, 2021, 64, 10581-10605.	2.9	56
474	A proteomic platform to identify off-target proteins associated with therapeutic modalities that induce protein degradation or gene silencing. Scientific Reports, 2021, 11, 15856.	1.6	7
475	Magic Rings: Navigation in the Ring Chemical Space Guided by the Bioactive Rings. Journal of Chemical Information and Modeling, 2022, 62, 2164-2170.	2.5	16
476	Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence. Pharmaceutics, 2021, 13, 1353.	2.0	21
477	Dual HDAC/BRD4 inhibitors against cancer. Medicinal Chemistry Research, 2021, 30, 1822-1836.	1.1	3
478	Recent Advances in In Silico Target Fishing. Molecules, 2021, 26, 5124.	1.7	29
479	Lymphoid Organ Proteomes Identify Therapeutic Efficacy Biomarkers Following the Intracavitary Administration of Curcumin in a Highly Invasive Rat Model of Peritoneal Mesothelioma. International Journal of Molecular Sciences, 2021, 22, 8566.	1.8	5
480	Combination Therapy for Bacterial Pathogens: Naturally Derived Antimicrobial Drugs Combined with Ulva lactuca Extract. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	2
481	Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA. Journal of Medicinal Chemistry, 2021, 64, 12630-12650.	2.9	38
482	Machine learning methods, databases and tools for drug combination prediction. Briefings in Bioinformatics, 2022, 23, .	3.2	45
483	Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90). Current Medicinal Chemistry, 2022, 29, 1474-1502.	1.2	11

#	Article	IF	Citations
484	4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads. Journal of Medicinal Chemistry, 2021, 64, 14620-14646.	2.9	22
485	Quantitative Polypharmacology Profiling Based on a Multifingerprint Similarity Predictive Approach. Journal of Chemical Information and Modeling, 2021, 61, 4868-4876.	2.5	18
486	Cashew Nut Shell Liquid (CNSL) as a Source of Drugs for Alzheimerâ€™s Disease. Molecules, 2021, 26, 5441.	1.7	8
487	The Specificity and Broad Multitarget Properties of Ligands for the Free Fatty Acid Receptors FFA3/GPR41 and FFA2/GPR43 and the Related Hydroxycarboxylic Acid Receptor HCA2/GPR109A. Pharmaceuticals, 2021, 14, 987.	1.7	4
488	Traditional Chinese medicine as a therapeutic option for cardiac fibrosis: Pharmacology and mechanisms. Biomedicine and Pharmacotherapy, 2021, 142, 111979.	2.5	19
489	Lanosterol 14Î±-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections. European Journal of Medicinal Chemistry, 2021, 221, 113524.	2.6	24
490	A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors In Vitro and In Vivo. Frontiers in Pharmacology, 2021, 12, 741697.	1.6	7
491	Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. Bioorganic and Medicinal Chemistry Letters, 2021, 49, 128286.	1.0	14
492	A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles. European Journal of Medicinal Chemistry, 2021, 222, 113569.	2.6	19
493	Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis. Bioorganic Chemistry, 2021, 116, 105350.	2.0	7
494	Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3Î² inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine. European Journal of Medicinal Chemistry, 2021, 223, 113663.	2.6	3
495	An in silico pipeline for the discovery of multitarget ligands: A case study for epi-polypharmacology based on DNMT1/HDAC2 inhibition. Artificial Intelligence in the Life Sciences, 2021, 1, 100008.	1.6	1
496	Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease. European Journal of Medicinal Chemistry, 2021, 226, 113847.	2.6	15
497	Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. European Journal of Medicinal Chemistry, 2021, 225, 113768.	2.6	52
498	De novo generation of dual-target ligands using adversarial training and reinforcement learning. Briefings in Bioinformatics, 2021, 22, .	3.2	7
499	G protein-coupled receptors: structure- and function-based drug discovery. Signal Transduction and Targeted Therapy, 2021, 6, 7.	7.1	241
500	The In Silico Fischer Lock-and-Key Model: The Combined Use of Molecular Descriptors and Docking Poses for the Repurposing of Old Drugs. Methods in Molecular Biology, 2020, 2089, 29-39.	0.4	7
501	Computational Modeling of Multi-target-Directed Inhibitors Against Alzheimerâ€™s Disease. Neuromethods, 2018, , 533-571.	0.2	6

#	Article	IF	Citations
502	Machine learning strategies for identifying repurposed drugs for cancer therapy. , 2020, , 55-79.		1
503	Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy. Bioorganic Chemistry, 2020, 101, 103970.	2.0	14
504	Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies. Trends in Pharmacological Sciences, 2020, 41, 172-182.	4.0	42
505	Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90. ACS Omega, 2020, 5, 11473-11480.	1.6	27
506	Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology. Journal of Biological Chemistry, 2020, 295, 17935-17949.	1.6	8
513	A simple mathematical approach to the analysis of polypharmacology and polyspecificity data. F1000Research, 2017, 6, 788.	0.8	12
514	Systematic, network-based characterization of therapeutic target inhibitors. PLoS Computational Biology, 2017, 13, e1005599.	1.5	23
515	Drug2ways: Reasoning over causal paths in biological networks for drug discovery. PLoS Computational Biology, 2020, 16, e1008464.	1.5	18
516	A Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases. PLoS Neglected Tropical Diseases, 2016, 10, e0004300.	1.3	38
517	Quantifying the Tendency of Therapeutic Target Proteins to Bind Promiscuous or Selective Compounds. PLoS ONE, 2015, 10, e0126838.	1.1	15
518	Similarities between the Binding Sites of SB-206553 at Serotonin Type 2 and Alpha7 Acetylcholine Nicotinic Receptors: Rationale for Its Polypharmacological Profile. PLoS ONE, 2015, 10, e0134444.	1.1	13
519	Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment. Cell Stress, 2020, 4, 154-166.	1.4	14
520	Repositioning of 8-hydroxyquinoline derivatives as a new promising candidate for combating multidrug resistant. EXCLI Journal, 2018, 17, 840-846.	0.5	15
521	Scorpion and spider venoms in cancer treatment: state of the art, challenges, and perspectives. , 2017, , .		16
522	Identification of deubiquitinase targets of isothiocyanates using SILAC-assisted quantitative mass spectrometry. Oncotarget, 2017, 8, 51296-51316.	0.8	14
523	Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. Oncotarget, 2018, 9, 21512-21529.	0.8	10
524	The Thiol-polyamine Metabolism of Trypanosoma cruzi: Molecular Targets and Drug Repurposing Strategies. Current Medicinal Chemistry, 2019, 26, 6614-6635.	1.2	22
525	Survey of Similarity-Based Prediction of Drug-Protein Interactions. Current Medicinal Chemistry, 2020, 27, 5856-5886.	1.2	32

#	Article	IF	Citations
526	In Silico Drug Repositioning for Chagas Disease. Current Medicinal Chemistry, 2020, 27, 662-675.	1.2	12
527	Therapeutic Potential of Natural Psychoactive Drugs for Central Nervous System Disorders: A Perspective from Polypharmacology. Current Medicinal Chemistry, 2020, 28, 53-68.	1.2	11
528	Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy. Current Medicinal Chemistry, 2020, 27, 7264-7288.	1.2	26
529	Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery. Current Topics in Medicinal Chemistry, 2016, 16, 2107-2114.	1.0	21
530	Phenotypic proteomic profiling identifies a landscape of targets for circadian clockâ€“modulating compounds. Life Science Alliance, 2019, 2, e201900603.	1.3	18
531	Synthetic Lethal Activity of Benzophenanthridine Alkaloids From Zanthoxylum coco Against BRCA1-Deficient Cancer Cells. Frontiers in Pharmacology, 2020, 11, 593845.	1.6	5
532	Design and Synthesis of Hsp90 Inhibitors with Bâ€Raf and PDHK1 Multiâ€Target Activity. ChemistryOpen, 2021, 10, 1177-1185.	0.9	5
533	Discovery of a Dual Tubulin and Poly(ADP-Ribose) Polymerase-1 Inhibitor by Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, and Biological Evaluation. Journal of Medicinal Chemistry, 2021, 64, 15702-15715.	2.9	22
534	Drug target inference by mining transcriptional data using a novel graph convolutional network framework. Protein and Cell, 2022, 13, 281-301.	4.8	18
535	The Use of Cannabis sativa L. for Pest Control: From the Ethnobotanical Knowledge to a Systematic Review of Experimental Studies. Cannabis and Cannabinoid Research, 2021, , .	1.5	1
536	Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2. Bioorganic and Medicinal Chemistry, 2021, 50, 116454.	1.4	2
537	Polypharmacology of dopamine D1-like receptor antagonists. Arhiv Za Farmaciju, 2015, 65, 287-303.	0.2	1
539	Repurposing drugs in oncology. Practical Oncology, 2017, 18, 139-158.	0.0	1
541	OBSOLETE: Topical Chemical Space in Relation to Biological Space. , 2019, , .		0
543	Benzofurocaine: effects on experimental periodontitis, anti-diabetic activity and molecular mechanisms of action. Research Results in Pharmacology, 2019, 5, 15-30.	0.1	2
544	Polypharmacological study of Ceritinib using a structure based in silico approach. Revista Bionatura, 2019, 4, 836-840.	0.1	1
548	Modelling bioactivities of combinations of whole extracts of edibles with a simplified theoretical framework reveals the statistical role of molecular diversity and system complexity in their mode of action and their nearly certain safety. PLoS ONE, 2020, 15, e0239841.	1.1	0
549	Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacological Reviews, 2021, 73, 1404-1433.	7.1	40

#	Article	IF	Citations
550	Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-). European Journal of Medicinal Chemistry, 2022, 227, 113963.	2.6	33
551	Knowledge-based approaches to drug discovery for rare diseases. Drug Discovery Today, 2022, 27, 490-502.	3.2	15
552	Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans. European Journal of Medicinal Chemistry, 2022, 227, 113961.	2.6	22
554	NO-HDAC dual inhibitors. European Journal of Medicinal Chemistry, 2022, 227, 113934.	2.6	9
555	A new approach for antimicrobial and antiviral activities of biocompatible nanocomposite based on cellulose, amino acid and graphene oxide. Colloids and Surfaces B: Biointerfaces, 2022, 209, 112172.	2.5	37
556	Strategies of Virtual Screening in Medicinal Chemistry. , 2020, , 194-225.		1
558	Tyrosine-Derived Novel Benzoxazine Active in a Rat Syngenic Mammary Tumor Model of Breast Cancer. Journal of Medicinal Chemistry, 2021, 64, 16293-16316.	2.9	7
559	Explainable machine learning predictions of dual-target compounds reveal characteristic structural features. Scientific Reports, 2021, 11, 21594.	1.6	11
564	Scorpion and spider venoms in cancer treatment: state of the art, challenges, and perspectives. Journal of Clinical and Translational Research, 2017, 3, 233-249.	0.3	19
565	Nitroxoline: a potent antimicrobial agent against multidrug resistant Enterobacteriaceae. EXCLI Journal, 2019, 18, 445-453.	0.5	8
566	Interplay Between Endocannabinoid System and Neurodegeneration: Focus on Polypharmacology. Current Medicinal Chemistry, 2021, 28, .	1.2	2
567	DrugEx v2: de novo design of drug molecules by Pareto-based multi-objective reinforcement learning in polypharmacology. Journal of Cheminformatics, 2021, 13, 85.	2.8	30
568	Molecular Modeling Techniques Applied to the Design of Multitarget Drugs: Methods and Applications. Current Topics in Medicinal Chemistry, 2022, 22, 333-346.	1.0	3
569	Theoretically exploring selective-binding mechanisms of BRD4 through integrative computational approaches. SAR and QSAR in Environmental Research, 2021, 32, 1-27.	1.0	4
570	In silico evidence of beauvericin antiviral activity against SARS-CoV-2. Computers in Biology and Medicine, 2022, 141, 105171.	3.9	9
571	Polypharmacology: The science of multi-targeting molecules. Pharmacological Research, 2022, 176, 106055.	3.1	45
572	Structure-Based Virtual Screening for Ligands of G Proteinâ€“Coupled Receptors: What Can Molecular Docking Do for You?. Pharmacological Reviews, 2021, 73, 1698-1736.	7.1	61
573	Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a sulfonyl moiety as potent dual inhibitors of PLK1 and BRD4. New Journal of Chemistry, 2022, 46, 1246-1259.	1.4	3

#	Article	IF	Citations
574	Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition. Cells, 2022, 11, 471.	1.8	21
575	New trinuclear nickel(II) complexes as potential topoisomerase I/IIÎ± inhibitors: in vitro DNA binding, cleavage and cytotoxicity against human cancer cell lines. Chemical Papers, 2022, 76, 2093-2109.	1.0	8
576	Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics, 2022, 14, 209.	2.0	26
577	Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy. Bioorganic Chemistry, 2022, 120, 105604.	2.0	7
579	Increasing the Value of Data Within a Large Pharmaceutical Company Through In Silico Models. Methods in Molecular Biology, 2022, 2425, 637-674.	0.4	2
580	Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARÎ³ and 5-HT4 Receptors. Frontiers in Pharmacology, 2022, 13, 812745.	1.6	4
581	Targeting purinergic receptors to attenuate inflammation of dry eye. Purinergic Signalling, 2023, 19, 199-206.	1.1	4
582	Comprehensive assessment of NR ligand polypharmacology by a multiplex reporter NR assay. Scientific Reports, 2022, 12, 3115.	1.6	2
583	On the development of B-Raf inhibitors acting through innovative mechanisms. F1000Research, 2022, 11, 237.	0.8	1
584	Discovery of Anticancer Hybrid Molecules by Supervised Machine Learning Models and in Vitro Validation in Drug Resistant Chronic Myeloid Leukemia Cells. Journal of Chemical Information and Modeling, 2022, 62, 1126-1146.	2.5	6
585	Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. Journal of Medicinal Chemistry, 2022, 65, 5149-5183.	2.9	28
586	Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisininâ€“HDAC Inhibitor Hybrids as Multitarget Drugs. Pharmaceuticals, 2022, 15, 333.	1.7	4
587	ARTIFICIAL INTELLIGENCE IN PHARMACY DRUG DESIGN. Asian Journal of Pharmaceutical and Clinical Research, 0, , 21-27.	0.3	2
588	CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes. Cancers, 2022, 14, 1345.	1.7	7
589	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy. Journal of Medicinal Chemistry, 2022, 65, 4818-4831.	2.9	15
590	1-[4-(2-Dimethylaminoethoxy)phenylcarbonyl]-3,5-Bis(3,4,5-Trimethoxybenzylidene)-4-Piperidone hydrochloride and Related Compounds: Potent Cytotoxins Demonstrating Greater Toxicity to Neoplasms Than Non-Malignant Cells. Medicinal Chemistry, 2022, 18, .	0.7	0
591	Pan-Phosphodiesterase Inhibitors Attenuate TGF-Î²-Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation. Pharmaceuticals, 2022, 15, 423.	1.7	4
592	NMS-873 Leads to Dysfunctional Glycometabolism in A p97-Independent Manner in HCT116 Colon Cancer Cells. Pharmaceutics, 2022, 14, 764.	2.0	5

#	Article	IF	Citations
593	Natural Products with Antitumor Potential Targeting the MYB-C/EBPÎ²-p300 Transcription Module. Molecules, 2022, 27, 2077.	1.7	5
594	Web support for the more efficient discovery of kinase inhibitors. Drug Discovery Today, 2022, , .	3.2	0
595	In vitro biological and in silico molecular docking and ADME studies of a substituted triazine-coordinated cadmium(II) ion: efficient cytotoxicity, apoptosis, genotoxicity, and nuclease-like activity plus binding affinity towards apoptosis-related proteins. BioMetals, 2022, , 1.	1.8	1
596	Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-a]pyrimidinone Acyclo C-Nucleosides Multitarget Agents. Molecules, 2022, 27, 2422.	1.7	4
597	Dual-targetÂinhibitors based on PARP1: new trend in the development of anticancer research. Future Medicinal Chemistry, 2022, 14, 511-525.	1.1	2
598	Design, synthesis, and biological evaluation of novel pyrido-dipyrimidines as dual topoisomerase II/FLT3 inhibitors in leukemia cells. Bioorganic Chemistry, 2022, 122, 105752.	2.0	2
599	Design, Synthesis, and Structure-Activity relationships of Evodiamine-Based topoisomerase (Top)/Histone deacetylase (HDAC) dual inhibitors. Bioorganic Chemistry, 2022, 122, 105702.	2.0	10
600	Triggered azobenzene-based prodrugs and drug delivery systems. Journal of Controlled Release, 2022, 345, 475-493.	4.8	51
601	Drug repurposing through virtual screening and in vitro validation identifies tigecycline as a novel putative HCV polymerase inhibitor. Virology, 2022, 570, 9-17.	1.1	1
602	Set-Theoretic Formalism for Treating Ligand-Target Datasets. Molecules, 2021, 26, 7419.	1.7	3
603	Discovery of a Novel Template, 7-Substituted 7-Deaza-4â€²-Thioadenosine Derivatives as Multi-Kinase Inhibitors. Pharmaceuticals, 2021, 14, 1290.	1.7	5
604	New Phenol Esters for Efficient pH-Controlled Amine Acylation of Peptides, Proteins, and Sepharose Beads in Aqueous Media. Bioconjugate Chemistry, 2022, 33, 172-179.	1.8	7
605	Artificial Intelligence (AI) in Drugs and Pharmaceuticals. Combinatorial Chemistry and High Throughput Screening, 2022, 25, 1818-1837.	0.6	17
606	Design and Synthesis of Hybrid Compounds as Epigenetic Modifiers. Pharmaceuticals, 2021, 14, 1308.	1.7	3
607	Novel Aurora A and Protein Kinase C (Î±, Î²1, Î²2, and Î¸) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity. Journal of Medicinal Chemistry, 2022, 65, 3134-3150.	2.9	8
608	Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation. Bioorganic Chemistry, 2022, 124, 105816.	2.0	10
621	Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 2022, 65, 6729-6747.	2.9	7
622	Classification of antiseizure drugs in cultured neuronal networks using multielectrode arrays and unsupervised learning. Epilepsia, 2022, , .	2.6	2

#	Article	IF	Citations
623	Gallium(III) Complex with Cloxyquin Ligands Induces Ferroptosis in Cancer Cells and Is a Potent Agent against Both Differentiated and Tumorigenic Cancer Stem Rhabdomyosarcoma Cells. Bioinorganic Chemistry and Applications, 2022, 2022, 1-12.	1.8	12
624	On the development of B-Raf inhibitors acting through innovative mechanisms. F1000Research, 0, 11, 237.	0.8	4
625	Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors. Journal of Medicinal Chemistry, 2022, 65, 6573-6592.	2.9	17
626	New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1346-1363.	2.5	20
627	New kinase and HDAC hybrid inhibitors: recent advances and perspectives. Future Medicinal Chemistry, 2022, 14, 745-766.	1.1	2
628	Artificial Neural Network-Based Study Predicts GS-441524 as a Potential Inhibitor of SARS-CoV-2 Activator Protein Furin: a Polypharmacology Approach. Applied Biochemistry and Biotechnology, 2022, 194, 4511-4529.	1.4	6
629	Off-targetP ML: an open source machine learning framework for off-target panel safety assessment of small molecules. Journal of Cheminformatics, 2022, 14, 27.	2.8	5
630	Network Pharmacology Approach for Medicinal Plants: Review and Assessment. Pharmaceuticals, 2022, 15, 572.	1.7	99
632	HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer. Pharmaceuticals, 2022, 15, 667.	1.7	15
633	Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2022, 65, 7746-7769.	2.9	14
634	PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	77
635	Design, Synthesis and Biological Evaluation of 1,3,5-Triazine Derivatives Targeting hA1 and hA3 Adenosine Receptor. Molecules, 2022, 27, 4016.	1.7	2
636	Recent advances in the development of EGFR degraders: PROTACs and LYTACs. European Journal of Medicinal Chemistry, 2022, 239, 114533.	2.6	16
637	Explainable machine learning for medicinal chemistry: exploring multi-target compounds. Future Medicinal Chemistry, 2022, 14, 1171-1173.	1.1	2
638	Traditional and Novel Computer-Aided Drug Design (CADD) Approaches in the Anticancer Drug Discovery Process. Current Cancer Drug Targets, 2023, 23, 333-345.	0.8	9
639	Emerging strategies to overcome resistance to third-generation EGFR inhibitors. Journal of Hematology and Oncology, 2022, 15, .	6.9	48
640	The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers. Bioorganic and Medicinal Chemistry, 2022, 70, 116922.	1.4	3
641	Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors. European Journal of Medicinal Chemistry, 2022, 240, 114573.	2.6	12

#	Article	IF	Citations
642	Emerging Promise of Computational Techniques in Anti-Cancer Research: At a Glance. Bioengineering, 2022, 9, 335.	1.6	15
643	An Antioxidant and Anti-ER Stress Combo Therapy Decreases Inflammation, Secondary Brain Damage and Promotes Neurological Recovery following Traumatic Brain Injury in Mice. Journal of Neuroscience, 2022, 42, 6810-6821.	1.7	6
645	Is the reductionist paradox an Achilles Heel of drug discovery?. Journal of Computer-Aided Molecular Design, 2022, 36, 329-338.	1.3	1
646	Designing drugs when there is low data availability: one-shot learning and other approaches to face the issues of a long-term concern. Expert Opinion on Drug Discovery, 2022, 17, 929-947.	2.5	6
647	Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity. Frontiers in Oncology, 0, 12, .	1.3	2
648	Effects of site-directed mutagenesis of GLP-1 and glucagon receptors on signal transduction activated by dual and triple agonists. Acta Pharmacologica Sinica, 2023, 44, 421-433.	2.8	2
649	Advances in Computational Polypharmacology. Molecular Informatics, 2022, 41, .	1.4	6
650	Uncovering Streptomyces-Derived Compounds as Cosmeceuticals for the Development of Improved Skin Photoprotection Products: An In Silico Approach to Explore Multi-Targeted Agents. Scientia Pharmaceutica, 2022, 90, 48.	0.7	1
651	Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies. Molecular Cancer Therapeutics, 2022, 21, 1674-1688.	1.9	5
652	Radiosynthesis and evaluation of [11C]AG-488, a dual anti-angiogenetic and anti-tubulin PET ligand. Bioorganic and Medicinal Chemistry Letters, 2022, 74, 128941.	1.0	0
653	Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity. European Journal of Medicinal Chemistry, 2022, 241, 114634.	2.6	6
654	Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines. Acta Pharmacologica Sinica, 2022, 43, 3080-3095.	2.8	23
655	Discovery of a 2,6-diarylpyridine-based hydroxamic acid derivative as novel histone deacetylase 8 and tubulin dual inhibitor for the treatment of neuroblastoma. Bioorganic Chemistry, 2022, 128, 106112.	2.0	5
656	Polypharmacology in Predicting Drug Toxicity: Drug Promiscuity. , 2022, , 593-623.		0
657	Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape. Frontiers in Pharmacology, 0, 13, .	1.6	2
658	De Novo Prediction of Drug Targets and Candidates by Chemical Similarity-Guided Network-Based Inference. International Journal of Molecular Sciences, 2022, 23, 9666.	1.8	2
659	Molecular Docking: Metamorphosis in Drug Discovery. , 0, , .		2
660	Molecular Docking: Principles, Advances, and Its Applications in Drug Discovery. Letters in Drug Design and Discovery, 2024, 21, 480-495.	0.4	9

#	Article	IF	Citations
662	Drug repositioning: A bibliometric analysis. Frontiers in Pharmacology, 0, 13, .	1.6	7
663	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity. Journal of Medicinal Chemistry, 2022, 65, 12200-12218.	2.9	11
664	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry, 2022, 65, 12838-12859.	2.9	12
665	Polypharmacology-based approach for screening TCM against coinfection of Mycoplasma gallisepticum and Escherichia coli. Frontiers in Veterinary Science, 0, 9, .	0.9	1
666	A heterobifunctional molecule recruits cereblon to an RNA scaffold and activates its PROTAC function. Cell Reports Physical Science, 2022, 3, 101064.	2.8	4
667	Hypothesis-generating proteome perturbation to identify NEU-4438 and acoziborole modes of action in the African Trypanosome. IScience, 2022, 25, 105302.	1.9	1
668	Recent Advances in PROTAC Technology Toward New Therapeutic Modalities. Chemistry and Biodiversity, 2022, 19, .	1.0	2
669	Drug reprofiling history and potential therapies against Parkinsonâ€™s disease. Frontiers in Pharmacology, 0, 13, .	1.6	2
670	Dual Inhibitors of AChE and BACE-1 for Reducing AÎ² in Alzheimerâ€™s Disease: From In Silico to In Vivo. International Journal of Molecular Sciences, 2022, 23, 13098.	1.8	8
671	Plant-derived natural products for drug discovery: current approaches and prospects. Nucleus (India), 2022, 65, 399-411.	0.9	41
672	KUALA: a machine learning-driven framework for kinase inhibitors repositioning. Scientific Reports, 2022, 12, .	1.6	3
673	Quercetin inhibits angiotensin II-induced vascular smooth muscle cell proliferation and activation of JAK2/STAT3 pathway: A target based networking pharmacology approach. Frontiers in Pharmacology, 0, 13, .	1.6	5
674	Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors. Bioorganic and Medicinal Chemistry, 2022, 74, 117067.	1.4	7
676	Multi-target-based polypharmacology prediction (mTPP): An approach using virtual screening and machine learning for multi-target drug discovery. Chemico-Biological Interactions, 2022, 368, 110239.	1.7	1
677	HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode. Bioorganic Chemistry, 2022, 129, 106181.	2.0	4
678	Dual Targeting Topoisomerase/G-Quadruplex Agents in Cancer Therapyâ€”An Overview. Biomedicines, 2022, 10, 2932.	1.4	2
679	Cys-loop receptors on cannabinoids: All high?. Frontiers in Physiology, 0, 13, .	1.3	2
681	Recent development of multi-targeted inhibitors of human topoisomerase II enzyme as potent cancer therapeutics. International Journal of Biological Macromolecules, 2023, 226, 473-484.	3.6	7

#	Article	IF	Citations
682	Design, synthesis and anti-ovarian cancer activities of thieno[2,3-d]pyrimidine based chimeric BRD4 inhibitor/nitric oxide-donator. European Journal of Medicinal Chemistry, 2023, 246, 114970.	2.6	4
683	Site-directed late-stage diversification of macrocyclic nannocystins facilitating anticancer SAR and mode of action studies. RSC Medicinal Chemistry, 2023, 14, 299-312.	1.7	3
684	Structure based design and evaluation of benzoheterocycle derivatives as potential dual HIV-1 protease and reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2023, 246, 114981.	2.6	3
685	Design, synthesis, biological evaluation and crystal structure determination of dual modulators of carbonic anhydrases and estrogen receptors. European Journal of Medicinal Chemistry, 2023, 246, 115011.	2.6	3
686	Structure-activity relationship studies of benzothiazole-phenyl analogs as multi-target ligands to alleviate pain without affecting normal behavior. Prostaglandins and Other Lipid Mediators, 2023, 164, 106702.	1.0	1
687	Natural product evodiamine-inspired medicinal chemistry: Anticancer activity, structural optimization and structure-activity relationship. European Journal of Medicinal Chemistry, 2023, 247, 115031.	2.6	7
688	The dual FAK-HDAC inhibitor MY-1259 displays potent activities in gastric cancers in vitro and in vivo. Bioorganic Chemistry, 2023, 131, 106328.	2.0	7
689	Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry, 2022, 65, 16541-16569.	2.9	7
691	In silico activity and ADMET profiling of phytochemicals from Ethiopian indigenous aloes using pharmacophore models. Scientific Reports, 2022, 12, .	1.6	3
692	Current Pharmacotherapy and Multi-Target Approaches for Alzheimerâ€™s Disease. Pharmaceuticals, 2022, 15, 1560.	1.7	18
693	Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer. Pharmacological Reviews, 2023, 75, 35-61.	7.1	12
695	Biological Evaluation of Valeriana Extracts from Argentina with Potent Cholinesterase Inhibition for the Treatment of Neurodegenerative Disorders and Their Comorbiditiesâ€"The Case of Valeriana carnosa Sm. (Caprifoliaceae) Studied in Mice. Pharmaceuticals, 2023, 16, 129.	1.7	1
696	Design and synthesis of novel rigid dibenzo[b,f]azepines through ring closure technique as promising anticancer candidates against leukaemia and acting as selective topoisomerase II inhibitors and DNA intercalators. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, .	2.5	10
697	A Synthetic Overview of Benzoxazines and Benzoxazepines as Anticancer Agents. ChemMedChem, 2023, 18, .	1.6	6
698	Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A2A adenosine receptors and histone deacetylases. Chinese Chemical Letters, 2024, 35, 108136.	4.8	1
699	Explaining Accurate Predictions of Multitarget Compounds with Machine Learning Models Derived for Individual Targets. Molecules, 2023, 28, 825.	1.7	4
700	Network Pharmacology: An Emphasis on Traditional Chinese Medicines and Its Adaptability for Ayurveda Medicines in India. International Journal of Medical Science and Clinical Research Studies, 2022, 02, .	0.0	1
701	Molecular docking/dynamics simulations, MEP analysis, bioisosteric replacement and ADME/T prediction for identification of dual targets inhibitors of Parkinsonâ€™s disease with novel scaffold. In Silico Pharmacology, 2023, 11, .	1.8	4

#	Article	IF	Citations
702	Iridiumâ€Catalyzed Chemoâ€, Diastereoâ€, and Enantioselective Allylâ€Allyl Coupling: Accessing All Four Stereoisomers of (E)â€1â€Borylâ€Substituted 1,5â€Dienes by Chirality Pairing. Angewandte Chemie - International Edition, 2023, 62, .	7.2	8
703	Iridiumâ€Catalyzed Chemoâ€, Diastereoâ€, and Enantioselective Allylâ€“Allyl Coupling: Accessing All Four Stereoisomers of (E)â€1â€Borylâ€Substituted 1,5â€Dienes by Chirality Pairing. Angewandte Chemie, 0, , .	1.6	0
704	Impact of the Substitution Pattern at the Basic Center and Geometry of the Amine Fragment on 5-HT6 and D3R Affinity in the 1H-Pyrrolo[3,2-c]quinoline Series. Molecules, 2023, 28, 1096.	1.7	1
705	Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors. Molecules, 2023, 28, 1061.	1.7	0
706	Synthesis, DFT calculations, and anti-proliferative evaluation of pyrimidine and selenadiazolopyrimidine derivatives as dual Topoisomerase II and HSP90 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38, .	2.5	5
707	Targeted protein degradation in cancers: Orthodox PROTACs and beyond. Innovation(China), 2023, 4, 100413.	5.2	4
708	Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188866.	3.3	10
709	Design, synthesis, and repurposing of O-aminoalkyl-sulfuretin analogs towards discovery of potential lead compounds as antileishmanial agents. European Journal of Medicinal Chemistry, 2023, 251, 115256.	2.6	7
710	Antitumor activity and mechanisms of dual EGFR/DNA-targeting strategy for the treatment of lung cancer with EGFRL858R/T790M mutation. Bioorganic Chemistry, 2023, 135, 106510.	2.0	5
711	Rational Design of N-Methylcarbamoylguanidinyl Derivatives as Highly Potent Dual-Target Chitin Hydrolase Inhibitors for Retarding Growth of Pest Insects. Journal of Agricultural and Food Chemistry, 2023, 71, 2817-2826.	2.4	2
712	Insights into the promising prospect of medicinal chemistry studies against neurodegenerative disorders. Chemico-Biological Interactions, 2023, 373, 110375.	1.7	1
713	Identification of Promising Drug Candidates against Prostate Cancer through Computationally-Driven Drug Repurposing. International Journal of Molecular Sciences, 2023, 24, 3135.	1.8	2
714	Computational drug repurposing by exploiting large-scale gene expression data: Strategy, methods and applications. Computers in Biology and Medicine, 2023, 155, 106671.	3.9	5
715	Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharmaceutica Sinica B, 2023, 13, 2425-2463.	5.7	18
716	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. International Journal of Molecular Sciences, 2023, 24, 4401.	1.8	4
717	3-[5-(1H-Indol-3-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]-propionic Acid as a Potential Polypharmacological Agent. Scientia Pharmaceutica, 2023, 91, 13.	0.7	2
718	Computer-aided drug design-based system pharmacology applications for the treatment of diabetes mellitus. , 2023, , 255-280.		0
719	Once Upon a Time Adenosine and Its Receptors: Historical Survey and Perspectives as Potential Targets for Therapy in Human Diseases. Topics in Medicinal Chemistry, 2023, , .	0.4	0

#	Article	IF	Citations
720	Human Polo-like Kinase Inhibitors as Antiplasmodials. ACS Infectious Diseases, 2023, 9, 1004-1021.	1.8	2
721	Small Molecule Degraders of Protein Tyrosine Phosphatase 1B and Tâ€Cell Protein Tyrosine Phosphatase for Cancer Immunotherapy. Angewandte Chemie, 0, , .	1.6	0
722	Small Molecule Degraders of Protein Tyrosine Phosphatase 1B and Tâ€Cell Protein Tyrosine Phosphatase for Cancer Immunotherapy. Angewandte Chemie - International Edition, 2023, 62, .	7.2	8
727	Machine learning resources for drug design. , 2023, , 663-678.		1
728	Computer-aided drug design: An overview. , 2023, , 39-68.		0
739	Target-Based Screening for Lead Discovery. , 2023, , 141-173.		0
743	Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and human soluble epoxide hydrolase (sEH) enzyme inhibitors: Interlinking the endocannabinoid system. , 2023, , 175-187.		0
775	Structure, function and drug discovery of GPCR signaling. Molecular Biomedicine, 2023, 4, .	1.7	4
797	Continuous Prompt for Chemical Language Model Aided Anticancer Synergistic Drug Combination Prediction. , 2023, , .		0